Summary
Both peptides fall into a similar broad context as Neuropeptides, although the details of how they are used and discussed still diverge. Their typical research and application settings separate fairly clearly: Semax is more often discussed in the realm of Neurology and brain health and Ophthalmology, whereas Setmelanotide is more often associated with the realm of Metabolic and endocrine. They also influence different molecular systems, with Semax tracking more closely to GPCR receptor while Setmelanotide centers more on Melanocortin receptor. Semax has a more synthetic analog origin, while Setmelanotide is closer to synthetic design background and their development context also differs, with Semax approved for Research use only while Setmelanotide is approved. Semax takes the form of a linear peptide, whereas Setmelanotide is closer to a cyclic peptide, while Setmelanotide incorporates d-amino acid substitution features that are not part of Semax.